Amid rising concern, pay-to-play clinical trials are drawing federal scrutiny
HYACINTH EMPINADO/STAT
The FDA has asked a committee to consider how the research community should handle clinical trials that rely on the controversial funding mechanism.
No hay comentarios:
Publicar un comentario